CARDIOPROGRESS
Foundation for the advancement of cardiology

Heart Disease Risk May Start Before Birth A woman's prepregnancy heart health is critical to both her health as well as the health of the children she gives birth to, according to researchers.

Cancer survivors may be at heightened risk of cardiovascular disease An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong evidence of efficacy and safety in this population.

High Biomarker Level Plus Diabetes Predict Bad PCI Outcomes Among patients with type 2 diabetes and coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI), those with a high platelet-to-lymphocyte ratio (PLR) at the time of their procedure had a significantly higher risk for major adverse cardiovascular and cerebrovascular events (MACCE) and stent thrombosis compared with similar patients with a low PLR during a median 2.4-year follow-up. Patients with PCI and a high PLR, but without type 2 diabetes, were not at increased risk for these outcomes compared with similar patients with a low PLR.

Dabigatran Recalled Over Potential Carcinogen Ascend Laboratories LLC is recalling 10 lots of the oral anticoagulant dabigatran etexilate capsules (75 mg and 150 mg) because of unacceptable levels of a potential carcinogen.

Treat to LDL Target or High-Intensity Statin for All With Clinical CAD: LODESTAR How secondary prevention statins are given to push LDL cholesterol levels lower, whether in a high-intensity statin regimen or by dosage titration to meet LDL targets, may make little difference to clinical outcomes, suggests a randomized trial.

Sports-Related Sudden Cardiac Arrest 'Extremely' Rare in Women Sports-related sudden cardiac arrest (Sr-SCA) appears to be extremely rare in women compared with men, despite similar characteristics and circumstances of occurrence, data from three European population-based registries suggest.

Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug in development by Merck has shown encouraging results in a phase 2 study. The study was presented by Christie Ballantyne, MD, Baylor College of Medicine, Houston, Texas at the recent American College of Cardiology (ACC) Scientific Session/World Congress of Cardiology (WCC) 2023.

Cardiovascular Risk Factors Rife in Argentine Cardiologists Despite cardiologists' knowledge about cardiovascular disease and risk factors, they have a high prevalence of these risk factors. This observation suggests poor working conditions for cardiologists of both sexes and a high prevalence of workplace gender violence for female cardiologists, according to a study conducted by the Argentine Society of Cardiology (SAC).

New Tool Better Estimates Cardiovascular Risk in People With Lupus A tool that incorporates lupus-related variables with traditional risk factors provides a much more accurate assessment of cardiovascular (CV) risk in patients with systemic lupus erythematosus (SLE), according to data presented at the annual meeting of the Canadian Rheumatology Association.

Dapagliflozin Gets Expanded Heart Failure Indication in Europe The European Commission (EC) has expanded the indication for dapagliflozin (Forxiga) to include heart failure (HF) across the full spectrum of left ventricular ejection fraction — including HF with mildly reduced and preserved ejection fraction, AstraZeneca has announced.

Cancer Identified as a New Cardiovascular Risk Factor A history of cancer is an independent predictor of major cardiovascular events in patients undergoing coronary angioplasty. Cancer should be considered a new cardiovascular risk factor in primary and secondary prevention.

Management of arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Treating this condition can be challenging due to progressive fibrosis, phenotypic variations and small patient cohorts limiting the feasibility of conducting meaningful clinical trials.

American Heart Association (AHA) Scientific Sessions 2022 AHA’s Scientific Sessions 2022 in hybrid mode took place on Nov. 5-7, 2022, at McCormick Place Convention Center in Chicago, IL.

ACC Calls for More Career Flexibility in Cardiology A new statement from the American College of Cardiology (ACC) is calling for a greater degree of career flexibility in the specialty to promote cardiologists' personal and professional well-being and preserve excellence in patient care.

American Heart Associated A new statement from the American College of Cardiology (ACC) is calling for a greater degree of career flexibility in the specialty to promote cardiologists' personal and professional well-being and preserve excellence in patient care.

American Heart Associations conference

Prof. Aronow's career path Dear colleagues! The Cardioprogress Foundation presents the excerpts from the memoirs of the International Journal of Heart and Vascular Diseases editorial board member Wilbert S. Aronov, a cardiologist, professor of medicine, member of the FACC, FAHA, FACP, FCCP, FASPC, AGSF, FGSA. Dr. Wilbert Solomon Aronow was born in New York City on October 30, 1931. His parents were Russian Jewish immigrants. His grandparents were rabbis in Russia. Doctor Aronov dedicated his professional career to medicine.

World Heart Day 2022 in Iloilo Iloilo province made history for hosting this year’s World Heart Day. It was chosen by the World Health Organization (WHO) as pilot area for the celebration. As highlight of the event, the whole façade of the Iloilo provincial capitol was illuminated on Thursday night, Sept. 29. The ceremonial event was led by Gov. Arthur Defensor Jr.; Department of Health (DOH) undersecretaries Dr. Kenneth Ronquillo and Atty. Charade Grande; DOH Western Visayas regional director, Dr. Adriano Zubaan; and representatives from WHO, Resolve to Save Lives, and World Heart Federation.

Climate change and health inequity a deadly mix for the most vulnerable: World Heart Federation Geneva, 29 September 2022 - On World Heart Day, the World Heart Federation (WHF) is calling for urgent action on climate change and health inequity, with millions more lives now at risk from cardiovascular disease, which is still the world’s biggest killer.

New ESC Guidelines for Cutting CV Risk in Noncardiac Surgery The European Society of Cardiology (ESC) guidelines on cardiovascular assessment and management of patients undergoing noncardiac surgery have seen extensive revision since the 2014 version. They still have the same aim — to prevent surgery-related bleeding complications, perioperative myocardial infarction/injury (PMI), stent thrombosis, acute heart failure, arrhythmias, pulmonary embolism, ischemic stroke, and cardiovascular (CV) death.